Toros Dincman, MD
Medical Oncology · Charleston, SCNPI 1457799454
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $125 of the $175 with a category attached, or 71.5%. Ipsen Biopharmaceuticals, Inc accounts for 71.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in SC, where the typical reported total is $1,989.
Across 2 payments — averaging $87.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$125
- Eisai Inc.$50
Across 28 payments — averaging $20,340 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$470K
- Biontech SE$57K
- AbbVie$36K
- AVEO Pharmaceuticals, Inc.$7K
What the payments were for
- Food & beverage$12571%
- Education$5029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Eisai Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONIVYDE$125
- SOMATULINE DEPOT$125
How this compares
$175 in reported general payments places this provider in the 10th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 144 | $387,701 |
| Abiraterone Acetate | 134 | $306,699 |
| XtandiEnzalutamide | 21 | $286,254 |
| EliquisApixaban | 29 | $17,835 |
| Exemestane | 20 | $2,273 |
| Famotidine | 14 | $847 |
| Prednisone | 155 | $565 |
| Bicalutamide | 22 | $545 |
| Ondansetron Hcl | 28 | $534 |
| Potassium Chloride | 15 | $310 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $211 |
| Gabapentin | 24 | $206 |
| Prochlorperazine Maleate | 15 | $198 |
| LoperamideLoperamide Hcl | 11 | $173 |
| Anastrozole | 15 | $144 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charleston
- Albert LockhartCharleston$54K
- Gene SaylorsCharleston$26K
- Mariam AlexanderCharleston$23K
- Theodore GourdinCharleston$21K
- John KaczmarCharleston$20K
- Kevin BeckerCharleston$9K
- Scott LindhorstCharleston$7K
- Carolyn BrittenCharleston$2K
- Rodney WilliamsCharleston$1K
- Oleksandra LupakCharleston$313
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.